McMaster University spinout Fusion Pharmaceuticals has filed for a $100m IPO in the US, putting shareholders such as Facit in line for exits.

Fusion Pharmaceuticals, a Canada-based cancer radiopharmaceuticals developer spun out of McMaster University, has filed for a $100m initial public offering on the Nasdaq Global Market. The company has not yet settled on a price range or determined the number of shares it will issue. Founded in 2014, Fusion Pharmaceuticals is developing targeted alpha therapeutics, a…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.